Cargando…

Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females. However, mammographic diagnosis is sometimes non-conclusive with a Breast imaging Reporting and Data System (Bi-RaDS) result of 0. Cancer antigen 15-3 (CA15-3) is the most widely used serum tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shuang, Yun, Zhi-Yuan, Cui, Ming-Ming, Meng, Hongxue, Qian, Cheng, Liu, Tiemin, Liu, Zhi-Ping, Wang, Rui-Tao, Yu, Kai-Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620216/
https://www.ncbi.nlm.nih.gov/pubmed/28978076
http://dx.doi.org/10.18632/oncotarget.18870
_version_ 1783267539177963520
author Fu, Shuang
Yun, Zhi-Yuan
Cui, Ming-Ming
Meng, Hongxue
Qian, Cheng
Liu, Tiemin
Liu, Zhi-Ping
Wang, Rui-Tao
Yu, Kai-Jiang
author_facet Fu, Shuang
Yun, Zhi-Yuan
Cui, Ming-Ming
Meng, Hongxue
Qian, Cheng
Liu, Tiemin
Liu, Zhi-Ping
Wang, Rui-Tao
Yu, Kai-Jiang
author_sort Fu, Shuang
collection PubMed
description Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females. However, mammographic diagnosis is sometimes non-conclusive with a Breast imaging Reporting and Data System (Bi-RaDS) result of 0. Cancer antigen 15-3 (CA15-3) is the most widely used serum tumor marker for breast cancer screening. Platelet distribution width (PDW) is an early indicator of platelet activation. Fibrinogen contributed to angiogenesis and distant metastasis. The aim of this study was to investigate the ability of CA15-3, PDW, and fibrinogen individually or in combination, to distinguish breast cancer from benign breast disease. 200 consecutive patients with breast cancer and 187 patients with benign breast disease were included in this retrospective study. Patients’ characteristics and hematologic tests data at initial diagnosis were collected. The benefit of adding PDW and fibrinogen to a model with only CA15-3 was evaluated as an increased in the area under the curve (AUC) obtained by receiver operating curve (ROC). CA15-3, PDW and fibrinogen are higher in breast cancer patients than in patients with benign breast disease. Single biomarkers had AUC values ranging from 0.687 for fibrinogen to 0.810 for CA15-3. In addition, the combination of PDW, CA15-3, and fibrinogen increased the AUC to 0.900 (0.866-0.928) (p<0.0001), significantly higher than those of any single marker. In conclusion, the combined use of CA15-3, PDW and fibrinogen may be clinically useful in discriminating between breast cancer and benign breast disease in non-conclusive mammography patients.
format Online
Article
Text
id pubmed-5620216
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56202162017-10-03 Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients Fu, Shuang Yun, Zhi-Yuan Cui, Ming-Ming Meng, Hongxue Qian, Cheng Liu, Tiemin Liu, Zhi-Ping Wang, Rui-Tao Yu, Kai-Jiang Oncotarget Research Paper Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females. However, mammographic diagnosis is sometimes non-conclusive with a Breast imaging Reporting and Data System (Bi-RaDS) result of 0. Cancer antigen 15-3 (CA15-3) is the most widely used serum tumor marker for breast cancer screening. Platelet distribution width (PDW) is an early indicator of platelet activation. Fibrinogen contributed to angiogenesis and distant metastasis. The aim of this study was to investigate the ability of CA15-3, PDW, and fibrinogen individually or in combination, to distinguish breast cancer from benign breast disease. 200 consecutive patients with breast cancer and 187 patients with benign breast disease were included in this retrospective study. Patients’ characteristics and hematologic tests data at initial diagnosis were collected. The benefit of adding PDW and fibrinogen to a model with only CA15-3 was evaluated as an increased in the area under the curve (AUC) obtained by receiver operating curve (ROC). CA15-3, PDW and fibrinogen are higher in breast cancer patients than in patients with benign breast disease. Single biomarkers had AUC values ranging from 0.687 for fibrinogen to 0.810 for CA15-3. In addition, the combination of PDW, CA15-3, and fibrinogen increased the AUC to 0.900 (0.866-0.928) (p<0.0001), significantly higher than those of any single marker. In conclusion, the combined use of CA15-3, PDW and fibrinogen may be clinically useful in discriminating between breast cancer and benign breast disease in non-conclusive mammography patients. Impact Journals LLC 2017-06-29 /pmc/articles/PMC5620216/ /pubmed/28978076 http://dx.doi.org/10.18632/oncotarget.18870 Text en Copyright: © 2017 Fu et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Fu, Shuang
Yun, Zhi-Yuan
Cui, Ming-Ming
Meng, Hongxue
Qian, Cheng
Liu, Tiemin
Liu, Zhi-Ping
Wang, Rui-Tao
Yu, Kai-Jiang
Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title_full Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title_fullStr Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title_full_unstemmed Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title_short Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
title_sort cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620216/
https://www.ncbi.nlm.nih.gov/pubmed/28978076
http://dx.doi.org/10.18632/oncotarget.18870
work_keys_str_mv AT fushuang cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT yunzhiyuan cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT cuimingming cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT menghongxue cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT qiancheng cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT liutiemin cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT liuzhiping cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT wangruitao cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients
AT yukaijiang cancerantigen153plateletdistributionwidthandfibrinogenincombinationtodistinguishbreastcancerfrombenignbreastdiseaseinnonconclusivemammographypatients